---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-25-000006"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T21:26:47.254969+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Q4 net loss $1.1B, EPS $(2.91); FY2024 revenue $3.2B falls 53%; guides 2025 rev $1.5-2.5B

## Summary
- Q4 revenue $1.0B (-66% YoY); GAAP net loss $1.1B vs net income $217M in Q4 2023.
- FY2024 revenue $3.2B (-53% YoY); GAAP net loss $3.6B; EPS $(9.28).
- FY2024 cost of sales 47% of net product sales, including $238M non-cash charge for manufacturing agreement termination.
- 2025 revenue guided $1.5-2.5B; expects first-half 2025 revenue only ~$0.2B due to seasonality.
- Filed three BLAs: next-gen COVID (PDUFA May 31), RSV for 18-59 (PDUFA June 12), flu/COVID combo.

## SEC filing metadata
- accession: 0001682852-25-000006
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000006/0001682852-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000006/mrna-20250214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-25-000006
- JSON: https://secwatch.observer/filing/0001682852-25-000006.json
- Plain text: https://secwatch.observer/filing/0001682852-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.